Chronic urticaria (CU) is a debilitating mast cell-driven disease, often refractory to standard therapy (i.e., antihistamines). Lirentelimab, an anti-Siglec-8 monoclonal antibody, selectively inhibits mast cells and depletes eosinophils.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
